Nor and Nordi Simeglutide Injection approved for chronic kidney disease in China.

On July 18th, Novo Nordisk announced that the National Medical Products Administration had officially approved the addition of chronic kidney disease indications for Ryo Taek, making it the first and only GLP-1 receptor agonist approved in China for lowering the risk of continuous decline in eGFR, end-stage renal disease, and cardiovascular death in adult patients with type 2 diabetes complicated by chronic kidney disease.